Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Blueprint Medicines Corp (NASDAQ: BPMC) closed at $88.90 in the last session, up 0.59% from day before closing price of $88.38. In other words, the price has increased by $0.59 from its previous closing price. On the day, 0.73 million shares were traded. BPMC stock price reached its highest trading level at $91.76 during the session, while it also had its lowest trading level at $86.56.
Ratios:
We take a closer look at BPMC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.66 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 5.93 whereas as Long-Term Debt/Eq ratio is at 5.30.
On August 21, 2023, Needham reiterated its Buy rating and also lowered its target price recommendation from $65 to $66.
Wells Fargo Upgraded its Equal Weight to Overweight on July 31, 2023, whereas the target price for the stock was revised from $55 to $82.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 28 ’24 when Landsittel Michael sold 5,000 shares for $95.00 per share. The transaction valued at 475,000 led to the insider holds 47,286 shares of the business.
Albers Jeffrey W. sold 25,073 shares of BPMC for $2,188,264 on Mar 20 ’24. The Director now owns 176,050 shares after completing the transaction at $87.28 per share. On Mar 15 ’24, another insider, Landsittel Michael, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 13,734 shares for $87.78 each. As a result, the insider received 1,205,606 and left with 47,286 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 5443551744 and an Enterprise Value of 5507032064. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.83 while its Price-to-Book (P/B) ratio in mrq is 41.62. Its current Enterprise Value per Revenue stands at 22.083 whereas that against EBITDA is -11.603.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $101.00, while it has fallen to a 52-week low of $43.89. The 50-Day Moving Average of the stock is 0.40%, while the 200-Day Moving Average is calculated to be 28.32%.
Shares Statistics:
According to the various share statistics, BPMC traded on average about 768.06K shares per day over the past 3-months and 547100 shares per day over the past 10 days. A total of 61.15M shares are outstanding, with a floating share count of 59.80M. Insiders hold about 2.33% of the company’s shares, while institutions hold 106.34% stake in the company. Shares short for BPMC as of 1711584000 were 4372399 with a Short Ratio of 5.69, compared to 1709164800 on 5136028. Therefore, it implies a Short% of Shares Outstanding of 4372399 and a Short% of Float of 9.6.
Earnings Estimates
The market rating for Blueprint Medicines Corp (BPMC) is a result of the insights provided by Blueprint Medicines Corporation analysts actively involved in the assessment.The consensus estimate for the next quarter is $50.83, with high estimates of $54.05 and low estimates of $25.43.
